Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
Sara Alosaimy, Taylor Morrisette, Abdalhamid M Lagnf, Leonor M. Rojas, Madeline King, Benjamin Pullinger, Athena L V Hobbs, Nicholson B. Perkins, Michael P. Veve, Jeannette Bouchard, Tristan Gore, Bruce M Jones, James Truong, Justin Andrade, Glen Huang, Reese Cosimi, S. Lena Kang‐Birken, Kyle C. Molina, Mark Biagi, Michael Pierce, Marco R. Scipione, Jing Zhao, Susan L. Davis, Michael J. Rybak
Abstract
Acinetobacter baumannii, particularly when carbapenem resistant (CRAB), is one of the most challenging pathogens in the health care setting. This is complicated by the fact that there is no consensus guideline regarding management of A. baumannii infections. However, the recent Infectious Diseases Society of America guidelines for treatment of resistant Gram-negative infections provided expert recommendations for CRAB management. The panel suggest using minocycline among tetracycline derivatives rather than eravacycline (ERV) until sufficient clinical data are available. Therefore, we present the largest multicenter real-world cohort in patients treated with ERV for A. baumannii, where the majority of isolates were CRAB (69.5%). Our analysis demonstrate that patients treated with ERV-based regimens achieved a 30-day mortality of 23.9% and had a low incidence of ERV-possible adverse events (2.1%). This study is important as it fills the gap in the literature regarding the use of a novel tetracycline (i.e., ERV) in the treatment of this challenging health care infection.